Improving Hypertrophic Cardiomyopathy Outcomes: Early Diagnosis, Management, and Targeted Agents on the Horizon

Hypertrophic cardiomyopathy (HCM) is the most common monogenic cardiovascular disorder. Mutations in the proteins encoding myofilament contractile components lead to a hypertrophied but nondilated left ventricle. Patients can have dyspnea, palpitations, chest pain, syncope, and exercise intolerance. In the past, HCM was thought to be rare, however better diagnostic imaging has led to increased recognition of the disease. Prospective studies have shown that current targeted management strategies, developed over the last 20 years, have reduced HCM-related morbidity and mortality. However, many patients with HCM experience diagnostic delays leading to belated treatment that has a large negative impact on patient quality of life.

The educational program Improving Hypertrophic Cardiomyopathy Outcomes: Early Diagnosis, Management, and Targeted Agents on the Horizon will review the recommended diagnostic testing to identify patients with HCM and the evidence-based guidelines for managing these patients and provide information about agents in development to manage HCM.

Jointly provided by the Potomac Center for Medical Education and Rockpointe

Supported by an educational grant from MyoKardia, Inc., a wholly owned subsidiary of Bristol Myers Squibb.

Click here for the PCME Privacy Policy